Benitec Biopharma (BNTC) EBT Margin (2019 - 2023)

Benitec Biopharma (BNTC) reported EBT Margin of 234828.57% for Q2 2023, down 2070.62% sequentially from 10818.52% in Q1 2023.

Benitec Biopharma (BNTC) EBT Margin (2019 - 2023) Analysis & Trends

Benitec Biopharma (BNTC) has 5 years of EBT Margin data on file, last reported at 234828.57% in Q2 2023.

For the quarter ending Q2 2023, EBT Margin changed N/A year-over-year to 234828.57%; the trailing twelve-month figure through Mar 2024 stood at 5689871.43% (down 563066261.0% YoY), and the FY2023 full-year result was 41292.0%, up 777512.0% from the prior year.
EBT Margin declined to 234828.57% in Q2 2023, from 10818.52% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 46220.0% in Q2 2020 to a low of 380100.0% in Q1 2021.
A 5-year average of 94732.58% and a median of 10818.52% in 2023 frame the typical range for EBT Margin.
Across the five-year window, EBT Margin slumped 37256071 bps in 2021 and soared 37260000 bps in 2022, its largest moves.
Tracing BNTC's EBT Margin over 5 years: stood at 2741.56% in 2019, then plunged by 12966 bps to 358200.0% in 2020, then soared by 94 bps to 19948.0% in 2021, then plunged by 127 bps to 45264.29% in 2022, then sank by 419 bps to 234828.57% in 2023.
Business Quant data shows BNTC's EBT Margin at 234828.57% in Q2 2023, 10818.52% in Q1 2023, and 45264.29% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Benitec Biopharma	46.45 Mn	46.45 Mn	-	-

Download Data